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The efficacy and safety of 0.3% tacrolimus gel and 0.5% 
tacrolimus cream compared with calcipotriol ointment 
were evaluated in adults (n=124) with mild to moderate 
plaque psoriasis. Treatment was twice daily for a maxi-
mum of 12 weeks. Clinical efficacy was assessed by the 
percentage change in the local psoriasis severity index of 
a target lesion between baseline and week 12. By week 
12, the median percentage changes in local psoriasis se-
verity index of the target lesions in the tacrolimus gel, 
tacrolimus cream and calcipotriol groups were 55.6%, 
50.0% and 58.6%, respectively (no statistically signifi-
cant differences). Clinical improvement was observed 
after one week and increased throughout the study. Ta-
crolimus-treated patients experienced more application 
site skin burning (tacrolimus gel and cream both 31.0% 
versus 7.5% for calcipotriol; p=0.011). Skin burning was 
mostly mild in intensity and decreased substantially af-
ter 1 week of treatment. There were no differences in the 
nature and incidence of infections and no clinically rele-
vant changes in laboratory values. Key words: psoriasis; 
tacrolimus; cream; gel; adults.
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Psoriasis is a common chronic inflammatory skin disorder 
that affects 1–3% of the world’s population (1). Although 
the aetiology of psoriasis remains unclear, it appears to 
be a T-cell-mediated disease that is heavily influenced 
by genetic and environmental factors (2, 3). Epidermal 
T cells, activated by a variety of dermal and epidermal 
cell signals from a site of injury or infection, release cy-
tokines which stimulate keratinocyte hyperproliferation 
by influencing the expression of keratinocyte surface 
molecules (4).
Current topical treatments for psoriasis include coal 
tar, anthralin/dithranol, corticosteroids, calcipotriol, 
retinoids and ultraviolet light, and although these 
medications can provide some relief and control of the 
symptoms, they can be associated with unwanted side 
effects (5). Therefore there is a need for a new topical 
treatment that can quickly and effectively improve the 
clinical signs and symptoms of psoriasis and which can 
be applied safely for prolonged periods of time.
A new possibility is the calcineurin inhibitor, tacro-
limus. Tacrolimus inhibits the transcription and release 
of interleukin (IL)-2 and other cytokines involved in 
causing psoriasis such as IL-3, IL-4, IL-5, interferon 
(IFN)-γ and tumour necrosis factor (TNF)-α (6, 7). 
Tacrolimus ointment was developed for the treatment 
of atopic dermatitis, where it has demonstrated signifi-
cant efficacy in both adults (8, 9) and children (10, 11). 
However, the penetration of the ointment formulation of 
tacrolimus was not sufficient in psoriasis patients, and 
two new tacrolimus preparations in the form of a gel 
and a cream were developed. Here we present the data 
from the first European study to compare the efficacy 
and safety of 0.3% tacrolimus gel and 0.5% tacrolimus 
cream with 0.005% calcipotriol in the treatment of mild 
to moderate plaque psoriasis in adults.
MATERIALS AND METHODS
Study design
This was a 14-week, randomized, three-arm, open-label, ob-
server-blinded, parallel group study conducted in 16 centres in 
5 European countries. The study was conducted in accordance 
with the ethical principles described in the Declaration of Hel-
sinki, and the Ethics Committee of each centre reviewed the 
protocol and granted approval before the start of the study. A 
screening visit was carried out on day 1 (baseline, treatment al-
location) and a target lesion was identified for further evaluation 
during the study. Assessments were conducted at weeks 1, 2, 4, 
8, 12 (end of treatment) and 14 (follow-up visit).
Patients
Following written informed consent from the patient, male and 
female patients aged 18 years or older who had experienced 
stable plaque psoriasis for at least 6 months prior to the start of 
the study were randomized to treatment. The patients were 
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required to have a total affected body surface area of ≤10%, 
and for the clinical assessment, one target lesion located on the 
trunk or extremities sized between 40 and 200 cm2 and with a 
local psoriasis severity index (LPSI) score of ≥5.
Randomization and blinding
The randomization schedule was generated by the study spon-
sor. Randomization was 1:1:1 and stratified by centre. All 
patients who entered the treatment period received a consecu-
tive unique patient number. This number was also printed on 
the sealed box containing the study drug tubes. As this was an 
open-label, observer-blinded study, the patients were asked not 
to show their study medication to the investigator. All used, 
partly used and unused tubes were returned in a sealed box at 
the end of the study, and the tubes were weighed to calculate 
medication usage throughout the treatment period.
Treatment
Patients applied either 0.3% tacrolimus gel, 0.5% tacrolimus 
cream or 0.005% calcipotriol ointment twice daily to all affected 
body areas. There was to be an interval of 10–14 h between 
applications. After clearance (defined as no scaling, thickening 
or redness of the skin), the lesions were to be treated for 7 ad-
ditional days. The maximum treatment period was 12 weeks.
Prohibited therapies during the study included intranasal or 
inhaled corticosteroids (>2 mg prednisolone equivalent/day), 
systemic and topical corticosteroids, light treatments, antipsori-
atics (tazarotene, tar, topical retinoids, psoralens, salicylic acid, 
anthralin), immunosuppressive drugs, chemotherapy agents, 
systemically administered drugs with the potential to alter 
tacrolimus concentrations (inhibitors/inducers of cytochrome 
P450 3A4 isoenzyme, e.g. clotrimazole, barbiturates), drugs that 
can exacerbate psoriasis (lithium salts, betaadrenergic blocking 
agents, antimalarials) and other medicated topical agents. Over 
the counter or prescribed non-steroidal anti-inflammatory drugs 
for arthritis or other inflammatory conditions were permitted as 
were non-medicated emollients, sunscreens on body areas un-
treated with study drug, and systemic anti-infective therapies.
Assessments
The foremost treatment comparison was between 0.3% tacro-
limus gel and 0.5% tacrolimus cream. The main assessment 
of clinical efficacy was the percentage change between day 1 
(baseline) and week 12 (end of treatment) in LPSI of the target 
lesion. LPSI was selected because the evaluation of a local target 
lesion was considered to be a more sensitive measurement of 
treatment efficacy. The LPSI of the target lesion was calcula-
ted by summing the severity ratings for erythema, induration 
and scaling using the scoring system from the psoriasis area 
severity index (PASI) (12) and the score ranged from 0 to a 
maximum of 12.
Additional clinical assessments included the change in LPSI 
of the target lesion over time, the change in total affected body 
surface area over time, the physician’s and patient’s assess-
ment of clinical response, and the cosmetic acceptability of 
each treatment.
Safety assessments during the study included the monitor-
ing of adverse events and vital signs as well as the clinical 
laboratory evaluations (sodium, potassium, calcium, chloride, 
magnesium, serum glutamic oxaloacetic transaminase (SGOT, 
AST), serum glutamic pyruvic transaminase (SGPT, ALT), 
alkaline phosphatase, lactate dehydrogenase (LDH), gamma 
glutamyl transferase (GGT), glucose, creatinine, urea, total 
and direct bilirubin; haematology profile: haematocrit, haemo-
globin, thrombocytes, erythrocytes, leucocytes). An adverse 
event was defined as any untoward occurrence in a patient 
during the study, regardless of whether it was related to the 
study treatment.
Statistical analyses
The planned sample size of 120 patients was based on feasibility 
(number of sites and length of time for recruitment) and the fact 
that this was a pilot study. Power calculations revealed that if 
the difference in mean percentage change of LPSI assessment 
was equal to 15 (assumed SD = 23.6), a power of 80% would 
be achieved with 40 patients per treatment group.
The statistical analysis was based on the intent-to-treat popu-
lation (full analysis set) which was defined as all randomized 
patients who received at least one application of study medi-
cation. The comparison of 0.3% tacrolimus gel versus 0.5% 
tacrolimus cream was analysed using the Wilcoxon rank-sum 
test. The additional efficacy assessments were also analysed by 
Wilcoxon rank-sum test or Cochran-Mantel-Haenszel test as 
appropriate, while Fisher’s exact test was used to compare the 
incidence of adverse events between treatment groups.
RESULTS
Patient demographics and baseline characteristics
In total, 124 patients comprised the intent-to-treat po-
pulation: 42 patients each in the 0.3% tacrolimus gel 
and 0.5% tacrolimus cream treatment groups and 40 
patients in the calcipotriol treatment group (Table I). 
The treatment groups were comparable with respect 
to demographics, mean duration of psoriasis, mean 
duration of current stable disease, and mean affected 
body surface area.
Patient disposition
More patients in the tacrolimus gel and calcipotriol 
treatment groups completed the 12-week treatment 
period (34 patients, 81.0% and 35 patients, 87.5%, re-
spectively) compared with the tacrolimus cream group 
(30 patients, 71.4%). Seven patients (16.7%) and 10 
patients (23.8%) in the tacrolimus gel and tacrolimus 
cream groups, respectively, discontinued the study 
prematurely for reasons other than complete clearance 
compared with 3 patients (7.5%) in the calcipotriol 
group. There were no major differences among the 
treatment groups in the reasons for discontinuation; ad-
verse events were the main reason in the tacrolimus gel 
(three patients, 7.1%) and calcipotriol (three patients, 
7.5%) treatment groups. In the tacrolimus cream group, 
two patients (4.8%) withdrew from the study because 
of an adverse event while two further patients were 
withdrawn because of lack of efficacy.
Ointment usage
The median daily study drug usage was 4.04 g, 4.85 g 
and 4.77 g for the tacrolimus gel, tacrolimus cream and 
calcipotriol treatment groups, respectively.
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Efficacy
Main efficacy assessment. The median percentage 
change in the LPSI of the target lesion between base-
line and week 12 was slightly lower in the tacrolimus 
gel and tacrolimus cream treatment groups (55.6% 
and 50%, respectively) compared with the calcipotriol 
group (58.6%). There were no statistically significant 
differences among treatment groups.
Additional efficacy assessments. Clinical improvement 
in the median percentage change in LPSI of the target 
lesion was observed in all three treatment groups after 
one week of treatment, and continued to increase during 
the study with improvement being swiftest and greatest 
in the patients applying calcipotriol (Fig. 1). The pa-
tients in the tacrolimus treatment groups experienced 
a greater decrease in total affected body surface area 
during the treatment period compared with the calci-
potriol-treated patients. The median percentage change 
in total affected body surface area between baseline and 
week 12 was 40%, 37.5% and 21.1% for the tacrolimus 
gel, cream and calcipotriol groups, respectively.
With respect to the physician’s assessment of re-
sponse at the target lesion, 44.4%, 45.2% and 48.6% of 
the patients in the tacrolimus gel, tacrolimus cream and 
calcipotriol groups received a rating of ‘much better’ at 
week 12 (Fig. 2). Altogether 47.2%, 51.6% and 51.4% 
of patients in the respective treatment groups rated their 
psoriasis as ‘much better’.
Cosmetic acceptability of the medication. Most pa-
tients in all three treatment groups found the odour 
of the study medications to be acceptable. However, 
significantly more patients applying calcipotriol were 
dissatisfied with regard to staining of clothes caused by 
the ointment (25.7% versus 2.8% for tacrolimus gel; 
Cochran-Mantel-Haenszel test p=0.0035 and versus 
6.5% for tacrolimus cream; p=0.025) and greasiness 
of the formulation (20% versus 0.0% for tacrolimus 
cream; Cochran-Mantel-Haenszel test p=0.0094 and 
versus 5.6% for tacrolimus gel; p=NS).
Safety
Twenty-six patients (61.9%) in the tacrolimus gel group, 
28 patients (66.7%) in the tacrolimus cream group and 
27 patients (67.5%) in the calcipotriol experienced 
adverse events during the study. Of these, 19 patients 
(45.2%), 24 patients (57.1%) and 13 patients (32.5%) in 
the respective treatment groups had causally related 
adverse events, most of which occurred at the site of 
treatment application and were mild to moderate in 
intensity. Application site skin burning was the most 
frequent adverse event reported by the patients applying 
tacrolimus gel and tacrolimus cream (both 31.0% versus 
7.5% in the calcipotriol group; Fisher’s exact test, 
p<0.011, Table II) followed by application site pruritus 
(tacrolimus gel 9.5% and tacrolimus cream 16.7%, ver-
sus 7.5% in the calcipotriol group; p=NS). Most cases 
of skin burning and pruritus were mild in intensity and 
decreased greatly in prevalence after the first week of 
treatment as the clinical condition of skin improved.
Skin burning, exacerbation of psoriasis and skin ir-
Table I. Patient demographics and baseline characteristics 
– number of patients (%)
 0.3% 0.5% 0.005%
 tacrolimus tacrolimus calcipotriol
Parameter gel (n = 42) cream (n = 42) (n = 40)
Age (years)
Mean (SD) 45.4 (15.3) 48.3 (15.0) 50.9 (14.1)
Min–Max 18–76 25–82 18–74
Sex
Male 26 (61.9) 33 (78.6) 26 (65.0)
Female 16 (38.1) 9 (21.4) 14 (35.0)
Ethnic group
Caucasian 41 (97.6) 39 (92.9) 39 (97.5)
Oriental 1 (2.4) 3 (7.1) 1 (2.5)
Duration of psoriasis 
 (years)
Mean (SD) 14.1 (12.2) 20.5 (15.3) 22.3 (14.0)
Min–Max 0.7–55.3 1.3–69.3 2.4–51.3
Duration of current stable 
 disease (months)
Mean (SD) 40.5 (60.1) 49.3 (84.5) 35.9 (46.5)
Min–Max 6.3–336.5 6.3–466.9 6.3–215.1
% BSA affected at 
 baseline
Mean (SD) 6.2 (2.4) 6.7 (2.1) 6.0 (2.2)
Min–Max 1–10 2–10 3–10
LPSI at baseline
Mean (SD) 7.0 (1.6) 7.1 (1.8) 7.5 (1.6)
Min–Max 5–12 4–12 5–11
PASI at baseline
Mean (SD) 6.8 (3.8) 7.5 (4.3) 6.9 (3.0)
Min–Max 1.4–21.8 1.7–19.5 1.4–14.0
Intent-to-treat population. BSA, body surface area; LPSI, local psoriasis 
severity index; PASI, psoriasis area severity index.
Fig. 1. Median percentage change from baseline over time in local psoriasis 
severity index (LPSI) of the target lesion, intent-to-treat population.
* = End of treatment
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ritation led to the withdrawal of three patients in the 
tacrolimus gel group while in the tacrolimus cream 
group, skin burning and a brain neoplasm (unlikely 
relationship to treatment) led to treatment discontinua-
tion in two patients. In the calcipotriol group, exacer-
bation of psoriasis in one patient and two cases of skin 
irritation led to withdrawal from the study. There were 
three serious adverse events reported in two patients 
during the study; none of the events were related to the 
study medication.
There were no differences among the three treatment 
groups in the nature and incidence of infections. There 
were no clinically relevant changes in laboratory values 
or vital signs throughout the study in any of the patients 
and no differences among treatment groups.
DISCUSSION
This is the first study to describe the efficacy and safety 
of the novel tacrolimus formulations, 0.3% tacrolimus 
gel and 0.5% tacrolimus cream, compared with 0.005% 
calcipotriol ointment in the treatment of mild to mode-
rate plaque psoriasis in adult patients. The study results 
showed that after 12 weeks of treatment the clinical 
efficacy of the 0.3% tacrolimus gel was comparable to 
that of calcipotriol. The efficacy of the 0.5% tacrolimus 
cream formulation was slightly lower compared with 
calcipotriol and tacrolimus gel. The calcipotriol-treated 
patients had the fastest improvement, although by week 
12, there was little difference between the calcipotriol 
and tacrolimus gel treatment groups. This may suggest 
that a longer treatment period may be necessary to 
achieve optimal efficacy with tacrolimus.
The higher incidence of causally related adverse 
events observed in the patients applying the tacrolimus 
formulations can be attributed to the higher incidence 
of skin burning; otherwise there were no differences 
among treatment groups in the incidence of drug-rela-
ted adverse events. Transient skin burning at the site 
of application is a common adverse effect associated 
with tacrolimus ointment (8–11) and this appears to be 
true for the tacrolimus gel and cream formulations. Skin 
burning normally lasts around 10 min (11) and for most 
patients in this study, discomfort was not sufficient to 
warrant discontinuation of treatment, and the preva-
Table II. Most common* adverse events and infections 
regardless of relationship to study drug – [No. of patients (%)]
 0.3% 0.5% 0.005% 
 tacrolimus tacrolimus calcipotriol
Parameter gel (n = 42) cream (n = 42) (n = 40)
Total 26 (61.9) 28 (66.7) 27 (67.5)
Application site
burning 13 (31.0) 13 (31.0) 3 (7.5)
pruritus 4 (9.5) 7 (16.7) 3 (7.5)
warmth 4 (9.5) 1 (2.4) 0 (0.0)
erythema 0 (0.0) 0 (0.0) 3 (7.5)
dryness 0 (0.0) 2 (4.8) 0 (0.0)
photosensitivity 0 (0.0) 2 (4.8) 0 (0.0)
Oedema, peripheral 0 (0.0) 1 (2.4) 2 (5.0)
Influenza 2 (4.8) 1 (2.4) 0 (0.0)
Laryngitis 1 (2.4) 0 (0.0) 2 (5.0)
Nasopharyngitis 3 (7.1) 3 (7.1) 3 (7.5)
Pruritus 1 (2.4) 0 (0.0) 2 (5.0)
Seborrhoeic dermatitis 1 (2.4) 0 (0.0) 2 (5.0)
Skin burning sensation 1 (2.4) 3 (7.1) 2 (5.0)
Headache 0 (0.0) 3 (7.1) 6 (15.0)
Flushing 1 (2.4) 4 (9.5) 0 (0.0)
Hypertension 2 (4.8) 0 (0.0) 1 (2.5)
Arthralgia 0 (0.0) 0 (0.0) 2 (5.0)
Intent-to-treat population.
*At least 4% of patients in any treatment group.
Fig. 2. Physician’s and patient’s assessment of resonse at the target lesion at week 12 (end of treatment).
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lence of skin burning decreased greatly as the clinical 
condition of the skin improved.
A potential weakness of the study was the possibility 
of observer bias. The patients were asked not to show 
their study medication to the investigator or discuss the 
type of topical treatment used, but it is possible that the 
patients may have unwittingly given some clue to the 
investigator. In addition, the higher incidence of skin 
burning observed in the patients applying the tacrolimus 
formulations may also have indicated to the investigator 
which study treatment had been randomized.
In conclusion, in this study setting, the two novel 
tacrolimus formulations demonstrated efficacy com-
parable with that of calcipotriol ointment, and 0.3% 
tacrolimus gel and 0.5% tacrolimus cream are possible 
therapeutic options for the treatment of mild to moderate 
plaque psoriasis in adults.
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